MARKET

COCP

COCP

Cocrystal Pharma Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.3868
-0.0050
-1.28%
Opening 13:28 05/18 EDT
OPEN
0.3910
PREV CLOSE
0.3918
HIGH
0.4100
LOW
0.3828
VOLUME
60.59K
TURNOVER
8.18K
52 WEEK HIGH
1.490
52 WEEK LOW
0.3700
MARKET CAP
37.70M
P/E (TTM)
-2.4100
1D
5D
1M
3M
1Y
5Y
Cocrystal Pharma to Present at the H.C. Wainwright Global Investment Conference
BOTHELL, Wash., May 18, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that James Martin, Chief Financial Officer and co-interim Chief Executive Officer, will present a Company overview at the H.C. Wainwright Global Investment Con...
GlobeNewswire · 5h ago
COCP: Cocrystal Pharma Releases 2022 1st Quarter Results and Provides an Update on the Current Pipeline Programs
By Thomas Kerr, CFA NASDAQ:COCP READ THE FULL COCP RESEARCH REPORT
Benzinga · 6d ago
Recap: Cocrystal Pharma Q1 Earnings
  Cocrystal Pharma (NASDAQ:COCP) reported its Q1 earnings results on Wednesday, May 11, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Benzinga · 05/11 12:35
BRIEF-Cocrystal Pharma Reports First Quarter 2022 Financial Results
reuters.com · 05/11 12:06
Cocrystal Pharma Reports First Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs and Milestones
Reported favorable preliminary data from the two initial cohorts in its Phase 1 study with CC-42344 for the treatment of pandemic and seasonal influenza AAnnounced a collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) to ev...
GlobeNewswire · 05/11 12:00
The Daily Biotech Pulse: Ampio Falls On Knee Osteoarthritis Trial Update, AstraZeneca's COVID-19 Antibody Data, CureVac-GSK's Bivalent COVID-19 Vaccine Data
Here's a roundup of top developments in the biotech space over the last 24 hours.
Benzinga · 04/21 14:15
Cocrystal, NIAID ink pact to explore COVID-19 protease inhibitors in preclinical studies
Cocrystal Pharma (NASDAQ:COCP) signed an agreement with the National Institute of Allergy and Infectious Diseases (NIAID) for preclinical studies evaluating the potential of  its 3CL protease inhibitors to treat COVID-19.
Seekingalpha · 04/21 13:48
Cocrystal Pharma Collaborates With The National Institute Of Allergy And Infectious Diseases To Evaluate COVID-19 Protease Inhibitors
Cocrystal Pharma, Inc. (NASDAQ:COCP) (“Cocrystal” or the “Company”) announces a Non-Clinical Evaluation Agreement (NCEA) with the National Institute of Allergy and Infectious Diseases (NIAID) for
Benzinga · 04/21 12:02
More
No Data
Learn about the latest financial forecast of COCP. Analyze the recent business situations of Cocrystal Pharma Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average COCP stock price target is 4.083 with a high estimate of 5.00 and a low estimate of 3.250.
High5.00
Average4.083
Low3.250
Current 0.3868
EPS
Actual
Estimate
-0.03-0.02-0.02-0.01
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 42
Institutional Holdings: 15.04M
% Owned: 15.43%
Shares Outstanding: 97.47M
TypeInstitutionsShares
Increased
11
720.33K
New
1
270
Decreased
8
312.79K
Sold Out
9
684.09K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-1.16%
Pharmaceuticals & Medical Research
-1.45%
Key Executives
President/Co-Chief Executive Officer
Sam Lee
Co-Chief Executive Officer/Chief Financial Officer
James Martin
Director
Roger Kornberg
Director
Richard Pfenniger
Independent Director
Phillip Frost
Independent Director
Anthony Japour
Independent Director
Steven Rubin
No Data
No Data
About COCP
Cocrystal Pharma, Inc. is a biotechnology company. The Company focuses on developing antiviral therapeutics that inhibit the essential viral replication function of RNA viruses causing acute and chronic viral diseases. The Company focuses on treating influenza virus, coronavirus, and norovirus infections by discovering and developing drug candidates targeting the viral replication process. The Company uses computational methods to screen and design product candidates using cocrystal structural information. The Company’s Hepatitis C Virus (HCV) Non-Nucleoside Polymerase Inhibitor CC-31244 is a pan-genotypic inhibitor of NS5B polymerase for the treatment of hepatitis C infection. The Company’s CC-42344 is a PB2 inhibitor for the treatment of influenza A infection. It has also developed chemical libraries consisting of non-nucleoside inhibitors, metal-binding inhibitors, and drug-like fragments.

Webull offers kinds of Cocrystal Pharma Inc stock information, including NASDAQ:COCP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, COCP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading COCP stock methods without spending real money on the virtual paper trading platform.